OWP Pharmaceuticals has filed a notice of an exempt offering of securities to raise $2,730,773.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, OWP Pharmaceuticals is raising up to $2,730,773.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Steve Bourne played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About OWP Pharmaceuticals
OWP Pharmaceuticals provides FDA approved epilepsy medications to patients at affordable prices in the United States. We have created a business model that has a significant tie to a Not for Profit organization named the ROW Foundation. Through this model both organizations have a vision to drastically improve the lives of epilepsy patients throughout the world including under-resourced patients outside of the United States through increase education, diagnosis and treatment.
To learn more about OWP Pharmaceuticals, visit http://www.owppharma.com/
OWP Pharmaceuticals Linkedin Page: https://www.linkedin.com/company/one-world-pharmaceuticals/
Contact:
Steve Bourne, Chief Financial Officer
847-722-0803
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.